Celldex Therapeutics Inc (CLDX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Celldex Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 38.10 $ — 91% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -14.0% failed
- More than 10% revenue growth is expected for the coming year 354.0% passed
- Share count grows by less than 3% a year 12.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -14,322.6% failed
- Gross margin at 40% or higher and without meaningful erosion 100.0% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 516 m net cash passed
- Operating cash flow covers the profits of the last three years 82 m failed
- Return on capital at 15% or higher, or up versus two years ago -54.0% failed
- Insiders hold at least 10% or are net buyers 0.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 49.8% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 15
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -4.35 | -4.57 – -3.95 | 2 | -11.6% | 11 |
| 12/31/2027 | -4.37 | -5.46 – -3.70 | 11 | -0.4% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -1.04 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.71 | – | 1 | -71.60 | -4,007.80 | -33 | -33 |
| 2025: Q1 | -0.81 | – | 1 | 345.50 | -7,740.40 | -54 | -55 |
| 2025: Q2 | -0.85 | – | 1 | -70.80 | -7,753.40 | -44 | -45 |
| 2025: Q3 | -1.01 | – | 0 | -100.00 | – | -49 | -49 |
| 2025: Q4 | -1.22 | – | 0 | -93.60 | -108,480.00 | -64 | -65 |
| 2026: Q1 | -1.18 | – | 0 | -97.80 | -524,566.70 | -66 | -67 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 7 | -133 | -129 | -18.99 | -113 | 265 | 383 |
| 2017 | 13 | -122 | -93 | -10.86 | -100 | 236 | 316 |
| 2018 | 10 | -156 | -151 | -14.48 | -75 | 124 | 156 |
| 2019 | 4 | -55 | -51 | -3.51 | -46 | 94 | 123 |
| 2020 | 7 | -63 | -60 | -2.02 | -40 | 209 | 236 |
| 2021 | 5 | -71 | -71 | -1.64 | -61 | 419 | 445 |
| 2022 | 2 | -115 | -112 | -2.40 | -104 | 326 | 353 |
| 2023 | 7 | -155 | -141 | -2.92 | -107 | 429 | 466 |
| 2024 | 7 | -195 | -158 | -2.45 | -158 | 747 | 792 |
| 2025 | 2 | -287 | -259 | -3.89 | -211 | 527 | 583 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Celldex Therapeutics, Inc., ein biopharmazeutisches Unternehmen, befasst sich mit der Entwicklung therapeutischer Antikörper für Patienten mit schweren entzündlichen, allergischen, Autoimmun- und anderen Erkrankungen.
| Employees | 198 |
|---|---|
| Headquarters | Hampton, NJ |
| Address | Perryville III Building, 08827 Hampton, United States |
| Phone | 908 200 7500 |
| Website | celldex.com |
| IPO Date | 10. Mar 2008 |
| ISIN | US15117B2025 |
| Stock Split | 1:15 on 02/11/2019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Anthony S. Marucci M.B.A. | Founder, President, CEO & Director | 1962 |
| Tibor Keler Ph.D. | Founder, Chief Scientific Officer & Executive VP | 1959 |
| Elizabeth Crowley | Chief Product Development Officer & Senior VP | 1972 |
| Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs | 1957 |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1945 |
| Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration | 1975 |
| Freddy A. Jimenez Esq. | Senior VP & General Counsel | 1969 |
| Ronald A. Pepin Ph.D. | Chief Business Officer & Senior VP | 1956 |
| Diane C. Young M.D. | Senior VP & Chief Medical Officer | 1957 |
| Teri L. Lawver | SVP & Chief Commercial Officer | 1967 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.